Progress of researches on toxoplasmosis vaccines based on the CRISPR/Cas9 technology

VernacularTitle:基于CRISPR/Cas9技术的弓形虫病疫苗研究进展
Author: Yan WU ^{1
,

2} ; Xin ZHANG ¹ ; Jin LI ¹ ; Jinjing XIE ¹ ; Longjiang WANG ¹ ; Hui SUN ^{1
,

2}
Author Information

1. Shandong Institute of Parasitic Diseases, Shandong First Medical University & Shandong Academy of Medical Sciences, Jining, Shandong 272033, China
2. School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China
Publication Type:Journal Article
Keywords: Toxoplasma gondii; CRISPR/Cas9 technology; Vaccine; Gene-deletion strain
From: Chinese Journal of Schistosomiasis Control 2024;36(5):542-547
CountryChina
Language:Chinese
Abstract: Toxoplasma gondii is an obligatory intracellular parasite which infects a variety of warm-blooded animals and causes toxoplasmosis. Toxoplasmosis seriously endangers human health and animal husbandry production. As one of the effective gene editing tools, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has been widely used for knockout of genes in T. gondii. This review summarizes the applications of the CRISPR/Cas9 technology in vaccines against single- and double-gene deletion strains of T. gondii, so as to provide insights into development of toxoplasmosis vaccines.